APAC Bioreactor Market size is poised to surpass USD 3.5 billion by 2028, according to a latest forecast report by Graphical Research.
The COVID-19 pandemic has positively impacted the business landscape. Rising demand for therapeutics due to increasing chronic and infectious disease burden has resulted in the expansion of manufacturing capacities with integration of high yield equipment. The biopharmaceuticals industry in Asia is undergoing remarkable growth with government support, favorable regulations, and enhanced funding scenario. The innovate in India program, for instance, was developed to accelerate biopharmaceutical discovery and research in collaboration with the Department of Biotechnology and World Bank. Such collaborative initiatives influencing the life sciences industry in the region.
Reusable bioreactors are majorly preferred in commercial large-scale manufacturing due to their high capacity. Rising number of diseases affecting general population will contribute to a jump in pharmaceuticals demand. With enhanced flexibility in complexity, validation, process security, and cost of goods, the adoption of single-use bioreactors recorded noteworthy uptick. However, concerns regarding limited volume capacity of single-use bioreactors and extractables would hamper the product quality and yield could impede the market growth up to some extent.
The yeast cells segment dominated over USD 67 million revenue in 2021, owing to growing use of yeast cell culture in bioprocessing in biotechnology industries. The utilization of yeast as a cell factory presents notable advantages such as growth at high cell density and ease of genetic manipulation. Bioreactors enable high biomass concentration of cells that offers advantages such as cell reuse and high dilution rate during continuous process.
Speaking about the bifurcation based on the molecule, the recombinant proteins segment is likely to garner significant traction over the forecast timeframe. It has been developed as a safer and cost-effective alternative to the extraction of proteins from natural sources. Extensive applications of recombinant proteins, from production to purification of biopharmaceutical, could boost product demand. Growing number of clinical trials and approvals of recombinant proteins will positively impact the industry outlook.
Browse detailed statistical insights from the report, “Asia Pacific Bioreactors Market Size Forecast 2028 By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Product Type (Single-use, Reusable), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By End-use (R&D Organizations, Biopharma Manufacturers, CMOs), Research Report, Country Outlook (China, Japan, India, South Korea, Australia, Singapore, Indonesia, Malaysia, Philippines, Thailand), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
The Contract Manufacturing Organization (CMO) end-users segment held around 13% market share in 2021. Contract manufacturing provides cost advantage associated with production facility, thus maximizing the operating profit. Several manufactures are outsourcing production to improve their competency and productivity in the region. The benefits offered to the firms with limited infrastructure and resources will further spur adoption of bioreactors in CMOs over the forecast period.
Growing focus on stem cell research in the Japan will boost the adoption rate of bioreactors in the country. Substantial increase in geriatric population base has contributed to rising chronic disease burden. This has resulted into significant demand for effective treatment therapies and shifted focus towards gene therapy and stem cell research. Moreover, the preference for advanced technologies will impel the industry growth potential.
The bioreactors in APAC market research report includes in-depth coverage of the industry with estimates & forecast in terms of volume in Kilotons & revenue in USD Million from 2017 to 2028, for the following segments:
Asia Pacific Market, By Product Type
Asia Pacific Market, By Cell
- Mammalian Cells
- Bacterial Cells
- Yeast Cells
Asia Pacific Market, By Molecule
- Monoclonal Antibodies
- Recombinant Proteins
- Stem Cells
- Gene Therapy
Asia Pacific Market, By End-use
- Research and Development (R&D) Organizations
- Biopharmaceutical (biopharma) Manufacturers
- Contract Manufacturing Organizations (CMOs)
The above information has been provided for the following countries:
- Asia Pacific
- South Korea